AACB/RCPAQAP Toxicology and Therapeutic Drugs Workshop
Event description
A two-day workshop organised by the AACB/RCPAQAP Toxicology and Therapeutic Drugs Advisory Committees.
The AACB/RCPAQAP Toxicology and Therapeutic Drugs Advisory Committees have organised back-to-back in-person workshops at the RCPAQAP facility with expert speakers designed to inform clinical laboratories that offer toxicology and TDM services about current and emerging challenges.
Method development, updates to accreditation requirements, new and emerging therapeutic drugs and challenges in staying current in the ever-changing drugs of abuse landscape.
Target audience:
Pathologists, Scientists, Researchers and other health professionals
Expected outcomes:
- An understanding of the process to set-up new TDM and Toxicology assays in your laboratory
- An understanding of the potential pitfalls with some immunoassay toxicology methods
- The changes needed to comply with the new ISO 4023 standard
- Better patient outcomes where appropriate TDM is available
- How new antibiotics, Cystic Fibrosis and TB drugs are changing lives
- What are the emerging drugs of abuse and how to stay current with detection and confirmation
- What is the expectation when a “Drug Screen” is requested
- Opportunities to interact with expert speakers
- Certificate of Attendance
- In-person event only
| Day 1: Tue 1 Apr | |
|
8:30 – 9:00 |
Registration |
| Welcome & Introduction - Peter Graham | |
| Session 1: Accreditation / EQA / QC TDM | |
|
09.00-09.30 |
QAP - identifying patient risk - Peter Graham + Dr Chris Farrell |
|
09.30-10.00 |
Monitoring quality of TDM assays across a network - Lisa Jolly |
| 10.00-10.30 | Source of therapeutic intervals - Professor Graham Jones + Danijela Kocic |
|
10.30–11.00 |
Morning tea |
| Session 2: TDM in routine laboratories | |
|
11.00-11.30 |
Setting up a MS assay for a new therapeutic drug - Danijela Kocic |
|
11.30-12.00 |
Offering a laboratory service for TB, CF and immunotherapy monitoring - Brett McWhinney |
|
12.00-12.30 |
Immunosuppressant Case Studies - Betty Sallustio |
|
12.30–1.30 |
Lunch |
| Session 3: Emerging fields | |
|
13.30-14.00 |
Latest Research in TDM - A/Professor Jane Carland |
| 14.00-14.30 | Anti-microbial drug TDM - Professor Debbie Marriott |
| 14.30-15.00 | Picking the right time point for TDM - Professor Jan-Willem Alffenaar |
| 3.00-3.15 | Afternoon Tea |
| Panel Discussions: Ask the experts | |
| 15.15-16.00 | Q&A - Special Drugs Advisory Committee |
| 16.00 | Meeting Close |
| 1600-1800 | Networking Drinks |
| Day 2: Wed 2 Apr | |
8:30 – 9:00 | Registration |
| Welcome & Introduction - Grant Moore | |
| Session 1: Accreditation | |
09.00-09.30 | Standard urine drug screen - what to order? - Professor Graham Jones |
09.30-10.00 | Un/suitability of AS/NZS4308 for clinical/medical laboratories - Grant Moore |
| 10.00-10.30 | EQA challenges with on-site drug testing - Bernadette James |
10.30–11.00 | Morning tea |
| Session 2: Medico-Legal challenges for the Toxicology Laboratory | |
11.00-11.30 | Medicinal cannabis - Helen Martin |
11.30-12.00 | Forensic toxicology - FASS - Lidcombe (To be confirmed) |
12.00-12.30 | Poppy seeds - food grade vs pharmacological - Chris Cruikshank |
12.30–1.30 | Lunch |
| Session 3: Common analytical issues encountered in the toxicology laboratory | |
13.30-14.00 | Immunoassay drug screens: cross-reactivity & different methodologies - Yoke Leong |
| 14.00-14.30 | Novel Benzodiazepine Detections in a Queensland Public Drug Screening Laboratory - Darren Allen |
| 14.30-15.00 | Nitazenes, Kava and synthetic cannabinoids - Tim Smith |
| 3.00-3.15 | Afternoon Tea |
| Panel Discussions: Ask the experts | |
| 15.15-16.00 | Q&A - Toxicology Advisory Committee |
| 16.00 | Meeting Close |
| 1600-1800 | Networking Drinks |
Travelling to the RCPAQAP Office:
Driving: We have created a map with available parking close by. View.
Public Transport: Our closest train station is St Leonards. It is approximately 8-10 minute walk to our office.
Tickets for good, not greed Humanitix dedicates 100% of profits from booking fees to charity
